The epidemiology of herpes zoster in patients with newly diagnosed cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 1, 2013, Pages 82-90

  Habel, Laurel A ^a   Ray, Gary Thomas ^a   Silverberg, Michael J ^a   Horberg, Michael A ^b   Yawn, Barbara P ^c   Castillo, Adrienne L ^a   Quesenberry, Charles P ^a   Li, Yan ^b   Sadier, Patricia ^d   Tran, Trung N ^d  

^a DIVISION OF RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c OLMSTED MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CORTICOSTEROID THERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEMATOLOGIC DISEASE; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT; PRIORITY JOURNAL;

EID: 84872168702     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0815     Document Type: Article

References (53)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81.
2. Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999;130:922-32.
3. Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011;86:88-93.
4. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations on the Advisory Committee on Practices (ACIP). MMWR 2008;57(No.RR-5):1-30.
5. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26-33.
6. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicellazoster virus. N Engl J Med 2000;342:635-45.
7. Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. Nurs Res 2009;58:105-14.
8. Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051-9.
9. Ramot B, Modan M, Berkowicz M, Meytes D, Shochat J. The relation between therapy and herpes zoster in Hodgkin's disease. Isr J Med Sci 1978;14:1014-8.
10. Feld R, Bodey GP. Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 1977;39:1018-25.
11. Maung ZT, Taylor PR, Robinson P, Moore J, Lucraft HH, Evans RG, et al. Patient education for self-referral and on-demand treatment for herpes zoster in lymphoma patients. Leuk Lymphoma 1993;11:447-52.
12. Pahuja R, Parikh PM, Charak BS, Rawat RS, Gopal R, Saikia TK, et al. Zoster-varicella infection in Hodgkin's disease. J Assoc Physicians India 1988;36:321-2.
13. Guinee VF, Guido JJ, Pfalzgraf KA, Giacco GG, Lagarde C, Durand M, et al. The incidence of herpes zoster in patients with Hodgkin's disease. An analysis of prognostic factors. Cancer 1985;56:642-8.
14. De Pauw BE, Janssen JT, Vaissier P, Haanen C. Occurrence of herpes zoster varicella infections after completion of treatment for Hodgkin's disease. Neth J Med 1983;26:301-3.
15. Cunningham J, Mauch P, Rosenthal DS, Canellos GP. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep 1982;66:1015-22.
16. Redon J, Herranz C, Montalar J, Navarro JR, Blanes A, Munarriz B, et al. [Infections due to herpes-varicella viruses in Hodgkin's disease (author's transl)]. Med Clin (Barc) 1981;76:377-80.
17. Gopal R, Advani SH, Dinshaw KT, Nair CN, Desai PB. Herpes-zoster in malignancy. J Assoc Physicians India 1980;28:125-32.
18. Mill WB, Frisse ME. Herpes zoster in Hodgkin's disease. Mo Med 1978;75:515-8.
19. Gof finet DR, Glatstein EJ, Merigan TC. Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med 1972;76:235-40.
20. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-10.
21. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44 Suppl 1:S1-26.
22. Tran T, Ray GT, Saddier P, Trigg M, Hayes N, Li Y, et al. Immunocompromised status of patients with hematologic and solid tumor malignancies: construction of a practical algorithm. American Society of Hematology 51st Annual Meeting and Exposition, 2009, Abstract http://ash.confex.com/ash/2009/webprogram/Paper24625.html (Accessed on October 19, 2012).
23. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9.
24. Marubini E, Valsecchi M. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester: John Wiley & Sons; 1995.
25. Dunst J, Steil B, Furch S, Fach A, Bormann G, Marsch W. Herpes zoster in breast cancer patients after radiotherapy. Strahlenther Onkol 2000;176:513-6.
26. Wright ET, Winer LH. Herpes zoster and malignancy. Arch Dermatol 1961;84:242-4.
27. McGregor RM. Herpes zoster, chicken-pox, and cancer in general practice. Br Med J 1957;1:84-7.
28. Rusthoven JJ, Ahlgren P, Elhakim T, Pinfold P, Reid J, Stewart L, et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988;148:1561-6.
29. Dreizen S, McCredie KB, Bodey GP, Keating MJ. Mucocutaneous herpetic infections during cancer chemotherapy. Postgrad Med 1988;84:181-90.
30. Elias AD, Ayash L, Frei E III, Skarin AT, Hunt M, Wheeler C, et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst 1993;85:559-66.
31. Feld R, Evans WK, DeBoer G. Herpes zoster in patients with small-cell carcinoma of the lung receiving combined modality treatment. Ann Intern Med 1980;93:282-3.
32. Huberman M, Fossieck BE Jr, Bunn PA Jr, Cohen MH, Ihde DC, Minna JD. Herpes zoster and small cell bronchogenic carcinoma. Am J Med 1980;68:214-8.
33. Schimpff S, Serpick A, Stoler B, Rumack B, Mellin H, Joseph JM, et al. Varicella-Zoster infection in patients with cancer. Ann Intern Med 1972;76:241-54.
34. Masci G, Magagnoli M, Gullo G, Morenghi E, Garassino I, Simonelli M, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology 2006;71:164-7.
35. Morison WL. Letter: Herpes simplex and herpes zoster in neoplasia. Lancet 1974;1:1293.
36. Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection 2011;39:537-44.
37. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005;40:169-74.
38. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:370-5.
39. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995;9:1153-8.
40. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004;4:108-15.
41. Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 1977;136:531-40.
42. Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005;118:1416.
43. Lee PP, Lee TL, Ho MH, Wong WH, Lau YL. Herpes zoster in juvenileonset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. Pediatr Infect Dis J 2006;25:728-32.
44. Wacker P, Hartmann O, Benhamou E, Salloum E, Lemerle J. Varicellazoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989;4:191-4.
45. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000;25:657-64.
46. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152:1172-81.
47. Leung TF, Chik KW, Li CK, Lai H, Shing MM, Chan PK, et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000;25:167-72.
48. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-6.
49. National Comprehensive Cancer Network. NCCN Guidelines v1.2007 Prevention and Treatment of Cancer-related Infections. 2007.
50. National Comprehensive Cancer Network. NCCN Guidelines v1.2012 Prevention and Treatment of Cancer-related Infections. 2012.
51. Cebrian-Cuenca AM, Diez-Domingo J, Rodriguez MS, Puig-Barbera J, Navarro-Perez J. Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract 2010;11:33.
52. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995;171:701-4.
53. Chaves SS, Santibanez TA, Gargiullo P, Guris D. Chickenpox exposure and herpes zoster disease incidence in older adults in the U.S. Public Health Rep 2007;122:155-9.